IanKerridge

Forum Replies Created

Viewing 6 posts - 1 through 6 (of 6 total)
  • Author
    Posts
  • in reply to: What is the new normal? What have we learned? #7274
    IanKerridge
    Participant

    One of the many problems with Donald Trump announcing that he is taking ‘off-label’ hydroxychloroquine is that it is explicitly anti-clinical trials and works completely against the generation of evidence and practice improvement. No wonder the CT sector in the US responded so quickly. Just when you think………..

    in reply to: What is the new normal? What have we learned? #7268
    IanKerridge
    Participant

    Great question about changing the discourse on clinical trials.

    Perhaps changing the algorithms that make up the ’20 questions to ask your doctor’ so that it BEGINS with:

    ‘Is there a clinical trial relevant to my disease and my situation that we should consider?’

    and

    ‘If not at this hospital – should I go somewhere else or can I accept it remotely?’

    in reply to: What is the new normal? What have we learned? #7249
    IanKerridge
    Participant

    Anita is absolutely right – everyone now is aware of the challenges of doing vaccine studies. It has become the talk of ‘virtual’ pubs – at least until real ones open! Everyone is also aware that such studies are the only way to ‘escape’ from the clutches of infectious diseases.

    Of course these same insights apply across the board….so perhaps COVID can be utilised to make very clear why we need research for civil reasons and economic reasons – and not simply clinical ones? ie research determines how we live and work, our salaries and our kids education! (May have broader political education!)

    in reply to: What is the new normal? What have we learned? #7241
    IanKerridge
    Participant

    We seem to have changed many aspects of clinical care during COVID. We see patients less often. We accept their own accounts of AEs. We do less tests. We take patients transport problems more seriously. Some of these changes are positive.

    So what ways can CT change for the better? Do less F2F? Do more tele-trials? Do less tests?

    Can we maintain quality but also reduce costs and burden of participation and conduct?

    in reply to: Sponsor considerations for prospective trial design #7234
    IanKerridge
    Participant

    This is such a great question! There is no doubt that COVID has forced us to examine many aspects of clinical work – and many of these changes may have positive impacts in future care. Do patients need to be seen so often? Do they need so many tests? can they be seen remotely more often? Can reviews be devolved to different professional groups? How can we make the elderly more computer literate?

    So the same should be true in the CT space? What ways of doing CT during COVID could we learn from and take forward? Do patients need to be seen so often? Can we simplify PIFs? Do we need to be so careful with AEs? can we do more on e-platforms?

    ian

    in reply to: HRECs and COVID-19 #7224
    IanKerridge
    Participant

    Yes – thankfully non-COVID trials are still being reviewed! Think how quiet we would be if not!

    Ian

Viewing 6 posts - 1 through 6 (of 6 total)

Disclaimer

The comments and resources posted here have been provided by members of Beyond COVID-19: A solution-focussed forum (‘Forum’) and other sources. They are offered for your reference only and are not intended to represent the best or only approach to any particular issue.

The Beyond COVID-19: A solution-focussed forum has not attempted to evaluate any posted material.

Neither ACTA, as host of the Forum, nor the individuals or collaborators on this Forum, make any guarantee with regard to the accuracy, completeness or suitability of any advice or resource, and they assume no responsibility or liability in connection with the use or misuse of any material.

The comments and resources posted here should not be construed as clinical or legal advice, and users should seek appropriate advice to address specific facts and circumstances.

Copyright in posted materials belongs to the respective owners, whether or not a copyright notice appears on the screen displaying the materials.